Abstract
Purpose: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated. We present the results of an Italian multicenter retrospective study, evaluating activity and toxicity of oxaliplatin-based chemotherapy in patients with advanced NETs. Methods: Clinical records from 5 referral centers were reviewed. Disease control rate (DCR) corresponding to PR+SD (partial response + stable disease) at 6 months, progression free survival (PFS), overall survival (OS) and toxicity were calculated. Ki67 labeling-index, grade of differentiation and excision-repair-cross-complementing group-1 (ERCC-1) were analyzed in tissue tumor samples. Results: Seventy-eight patients entered the study. Primary sites were: pancreas in 46, gastrointestinal in 24, lung in 19, and unknown in 10% patients. The vast majority were G2 (2010 WHO classification). Eighty-six percent of patients were metastatic, 87% pretreated and progressive to previous therapies. 65% patients received capecitabine/oxaliplatin (CAPOX), 6% gemcitabine/oxaliplatin (GEMOX), 29% leucovorin/fluorouracil/oxaliplatin (FOLFOX-6). Partial response occurred in 26% patients, half of them with pancreatic NETs (PNETs), and SD in 54%. With 21 months median follow-up, the median PFS and OS were 8 and 32 months with 70 and 45 events, respectively. The most frequent G3 toxicities were neurological and gastrointestinal. ERCC-1 immunohistochemical over-expression was positive in 4/28 evaluated samples, with no significant correlation with clinical outcome. Conclusion: This analysis suggests that oxaliplatin-based chemotherapy can be active with a manageable safety profile in advanced NETs irrespective of the primary sites and tumor grade. The 80% DCR and 8 months PFS could justify a prospective study in NETs with intermediate biological characteristics, especially with pancreatic primary. © 2016 S. Karger AG, Basel
| Original language | English |
|---|---|
| Journal | Neuroendocrinology |
| DOIs | |
| Publication status | Accepted/In press - Jan 21 2016 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Endocrine and Autonomic Systems
- Cellular and Molecular Neuroscience
Cite this
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors : Clinical Outcomes and Preliminary Correlation with Biological Factors. / Spada, Francesca; Antonuzzo, Lorenzo; Marconcini, Riccardo; Radice, Davide; Antonuzzo, Andrea; Ricci, Sergio; Di Costanzo, Francesco; Fontana, Annalisa; Gelsomino, Fabio; Luppi, Gabriele; Nobili, Elisabetta; Galdy, Salvatore; Cella, Chiara Alessandra; Sonzogni, Angelica Maria; Pisa, Eleonora; Barberis, Massimo; Fazio, Nicola.
In: Neuroendocrinology, 21.01.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors
T2 - Clinical Outcomes and Preliminary Correlation with Biological Factors
AU - Spada, Francesca
AU - Antonuzzo, Lorenzo
AU - Marconcini, Riccardo
AU - Radice, Davide
AU - Antonuzzo, Andrea
AU - Ricci, Sergio
AU - Di Costanzo, Francesco
AU - Fontana, Annalisa
AU - Gelsomino, Fabio
AU - Luppi, Gabriele
AU - Nobili, Elisabetta
AU - Galdy, Salvatore
AU - Cella, Chiara Alessandra
AU - Sonzogni, Angelica Maria
AU - Pisa, Eleonora
AU - Barberis, Massimo
AU - Fazio, Nicola
PY - 2016/1/21
Y1 - 2016/1/21
N2 - Purpose: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated. We present the results of an Italian multicenter retrospective study, evaluating activity and toxicity of oxaliplatin-based chemotherapy in patients with advanced NETs. Methods: Clinical records from 5 referral centers were reviewed. Disease control rate (DCR) corresponding to PR+SD (partial response + stable disease) at 6 months, progression free survival (PFS), overall survival (OS) and toxicity were calculated. Ki67 labeling-index, grade of differentiation and excision-repair-cross-complementing group-1 (ERCC-1) were analyzed in tissue tumor samples. Results: Seventy-eight patients entered the study. Primary sites were: pancreas in 46, gastrointestinal in 24, lung in 19, and unknown in 10% patients. The vast majority were G2 (2010 WHO classification). Eighty-six percent of patients were metastatic, 87% pretreated and progressive to previous therapies. 65% patients received capecitabine/oxaliplatin (CAPOX), 6% gemcitabine/oxaliplatin (GEMOX), 29% leucovorin/fluorouracil/oxaliplatin (FOLFOX-6). Partial response occurred in 26% patients, half of them with pancreatic NETs (PNETs), and SD in 54%. With 21 months median follow-up, the median PFS and OS were 8 and 32 months with 70 and 45 events, respectively. The most frequent G3 toxicities were neurological and gastrointestinal. ERCC-1 immunohistochemical over-expression was positive in 4/28 evaluated samples, with no significant correlation with clinical outcome. Conclusion: This analysis suggests that oxaliplatin-based chemotherapy can be active with a manageable safety profile in advanced NETs irrespective of the primary sites and tumor grade. The 80% DCR and 8 months PFS could justify a prospective study in NETs with intermediate biological characteristics, especially with pancreatic primary. © 2016 S. Karger AG, Basel
AB - Purpose: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated. We present the results of an Italian multicenter retrospective study, evaluating activity and toxicity of oxaliplatin-based chemotherapy in patients with advanced NETs. Methods: Clinical records from 5 referral centers were reviewed. Disease control rate (DCR) corresponding to PR+SD (partial response + stable disease) at 6 months, progression free survival (PFS), overall survival (OS) and toxicity were calculated. Ki67 labeling-index, grade of differentiation and excision-repair-cross-complementing group-1 (ERCC-1) were analyzed in tissue tumor samples. Results: Seventy-eight patients entered the study. Primary sites were: pancreas in 46, gastrointestinal in 24, lung in 19, and unknown in 10% patients. The vast majority were G2 (2010 WHO classification). Eighty-six percent of patients were metastatic, 87% pretreated and progressive to previous therapies. 65% patients received capecitabine/oxaliplatin (CAPOX), 6% gemcitabine/oxaliplatin (GEMOX), 29% leucovorin/fluorouracil/oxaliplatin (FOLFOX-6). Partial response occurred in 26% patients, half of them with pancreatic NETs (PNETs), and SD in 54%. With 21 months median follow-up, the median PFS and OS were 8 and 32 months with 70 and 45 events, respectively. The most frequent G3 toxicities were neurological and gastrointestinal. ERCC-1 immunohistochemical over-expression was positive in 4/28 evaluated samples, with no significant correlation with clinical outcome. Conclusion: This analysis suggests that oxaliplatin-based chemotherapy can be active with a manageable safety profile in advanced NETs irrespective of the primary sites and tumor grade. The 80% DCR and 8 months PFS could justify a prospective study in NETs with intermediate biological characteristics, especially with pancreatic primary. © 2016 S. Karger AG, Basel
UR - http://www.scopus.com/inward/record.url?scp=84955601957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955601957&partnerID=8YFLogxK
U2 - 10.1159/000444087
DO - 10.1159/000444087
M3 - Article
JO - Neuroendocrinology
JF - Neuroendocrinology
SN - 0028-3835
ER -